The #SBIR/#STTR #NIH, #CDC, and #FDA solicitation open

The 2019 #SBIR and #STTR Omnibus/Parent #Grant Solicitations for the #NIH, #CDC, and #FDA was recently released. Wondering what they will fund?

Be sure to pay close attention to the slight differences between #NIH, #CDC, #FDA, and between #SBIR and #STTR, as well as “clinical trial allowed” or “not allowed”. Each has specific requirements that are unique to the solicitation line. Need help determining whether you are doing a clinical trial?

Please note that all proposals are due by 5:00 PM local time of applicant organization on September 5 for Cycle I, January 5 for Cycle II, and April 5 for Cycle III.

Approved 2019 Program Descriptions and Research Topics Documents are here (PDF 2.31 MB) (MS WORD 614 KB), be sure that what you are proposing fits within the approved topics list.

  • #NIH, #CDC, and #FDA’s #SBIR (PA-19-272) – clinical trials are NOT ALLOWED and will accept the following application types:
    • New (Phase I, Fast-Track (NIH-only)),
    • New (SBIR Direct Phase II – NIH Only),
    • Renewal (Phase II),
    • Resubmission (all phases),
    • Renewal (Phase IIB)
  • #NIH, #CDC, and #FDA’s #STTR (PA-19-270) – clinical trials are NOT ALLOWED and will accept the following application types:
    • New (Phase I, Fast-Track)
    • Renewal (Phase II* Direct Phase II NOT allowed)
    • Resubmission (all phases)
    • Renewal (Phase IIB)
    • Revision
  • #NIH, #CDC, and #FDA’s #SBIR (PA-19-273) – clinical trials ARE ALLOWED and will accept the following application types:
    • New (Phase I, Fast-Track (NIH-only))
    • New (SBIR Direct Phase II – NIH Only)
    • Renewal (Phase II)
    • Resubmission (all phases)
    • Renewal (Phase IIB)
    • Revision
  • #NIH, #CDC, and #FDA’s #STTR (PA-19-271) – clinical trials ARE ALLOWED and will accept the following application types:
    • New (Phase I, Fast-Track)
    • Renewal (Phase II* Direct Phase II NOT allowed)
    • Resubmission (all phases)
    • Renewal (Phase IIB)
    • Revision

Ready To Take the Next Step?

Schedule a Consult Call

We assist our clients in locating, applying for, and evaluating the outcomes of non-dilutive grant funding. We believe non-dilutive funding is a crucial tool for mitigating investment risks, and we are dedicated to guiding our clients through the entire process—from identifying the most suitable opportunities to submitting and managing grant applications.